| Date | Time | Source | Announcement |
|---|---|---|---|
| 30 Mar 2009 | 05:30 PM | Director/PDMR Shareholding | |
| 30 Mar 2009 | 05:30 PM | Director/PDMR Shareholding | |
| 25 Mar 2009 | 04:30 PM | Director/PDMR Shareholding | |
| 25 Mar 2009 | 04:30 PM | Director/PDMR Shareholding | |
| 20 Mar 2009 | 04:30 PM | Annual Information Update | |
| 17 Mar 2009 | 06:02 PM | Filing of 20-F | |
| 04 Mar 2009 | 03:03 PM | Annual Report and Accounts | |
| 02 Mar 2009 | 07:00 AM | Symbicort COPD | |
| 27 Feb 2009 | 04:00 PM | Total Voting Rights | |
| 27 Feb 2009 | 10:00 AM | Board change | |
| 27 Feb 2009 | 07:00 AM | Seroquel XR CRL for GAD | |
| 26 Feb 2009 | 04:30 PM | Director/PDMR Shareholding | |
| 26 Feb 2009 | 04:30 PM | Director/PDMR Shareholding | |
| 26 Feb 2009 | 04:30 PM | Director/PDMR Shareholding | |
| 25 Feb 2009 | 04:30 PM | Director/PDMR Shareholding | |
| 25 Feb 2009 | 04:30 PM | Director/PDMR Shareholding | |
| 25 Feb 2009 | 01:00 PM | Seroquel XR | |
| 24 Feb 2009 | 07:00 AM | AstraZeneca and MAP: UDB | |
| 30 Jan 2009 | 04:00 PM | Total Voting Rights | |
| 29 Jan 2009 | 11:00 AM | Final Results - part 3 of 3 | |
| 29 Jan 2009 | 11:00 AM | Final Results - part 2 of 3 | |
| 29 Jan 2009 | 11:00 AM | AstraZeneca and Pozen : PN400 | |
| 29 Jan 2009 | 11:00 AM | Currency Sensitivity Guide | |
| 29 Jan 2009 | 11:00 AM | Final Results - part 1 of 3 | |
| 28 Jan 2009 | 09:00 AM | Notice of Results | |
| 22 Jan 2009 | 12:00 PM | Director/PDMR Shareholding | |
| 06 Jan 2009 | 08:00 AM | MedImmune Submits Marketing Authorisation Appli... | |
| 05 Jan 2009 | 04:00 PM | Total Voting Rights | |
| 24 Dec 2008 | 07:00 AM | Seroquel XR CRL | |
| 19 Dec 2008 | 12:38 PM | AstraZeneca and Map Pharmaceu | |
| 12 Dec 2008 | 07:00 AM | FDA AdCom on Symbicort | |
| 11 Dec 2008 | 11:00 AM | Return of Rights to Infinity | |
| 09 Dec 2008 | 07:00 AM | Topline phase IIb results for | |
| 08 Dec 2008 | 12:30 PM | AstraZeneca and BMS - Dapagli | |
| 03 Dec 2008 | 01:00 PM | PN 400 Phase III Studies | |
| 28 Nov 2008 | 04:00 PM | Total Voting Rights | |
| 28 Nov 2008 | 07:00 AM | MOTAVIZUMAB CRL | |
| 26 Nov 2008 | 07:00 AM | Pulmicort Respules US litigat | |
| 25 Nov 2008 | 07:00 AM | Update on Abraxis agreement | |
| 20 Nov 2008 | 07:00 AM | Pulmicort | |
| 19 Nov 2008 | 03:45 PM | Pulmicort | |
| 19 Nov 2008 | 07:00 AM | Pulmicort | |
| 19 Nov 2008 | 07:00 AM | Zactima | |
| 13 Nov 2008 | 07:00 AM | Regulatory Approval | |
| 10 Nov 2008 | 07:00 AM | Crestor JUPITER study results | |
| 04 Nov 2008 | 07:00 AM | Directorate Change | |
| 31 Oct 2008 | 04:00 PM | Total Voting Rights | |
| 30 Oct 2008 | 11:00 AM | 3rd Quarter Results - Part 2 | |
| 30 Oct 2008 | 11:00 AM | 3rd Quarter Results - Part 1 | |
| 29 Oct 2008 | 09:00 AM | Notice of Results |
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.
It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.
Astra Zeneca share price launched at 605p in 1993.